Skip to main content
Premium Trial:

Request an Annual Quote

BGI Americas Collaborating With Champions Oncology on Proteomic Cancer Research

NEW YORK – BGI Americas said on Tuesday that it has entered a collaborative agreement with Champions Oncology to provide proteomics and multiomics tools for cancer biomarker discovery and validation.

Under the collaboration, BGI will provide mass spectrometry analysis of Champions' patient-derived xenograft samples to support biopharma drug discovery and development projects.

BGI will handle sample preparation and mass spec analysis, generating proteomics and metabolomic data out of its San Jose, California-based Mass Spectrometry Center. The collaboration will also give BGI's customers access to Champions' Lumin Bioinformatics platform, a data visualization software package that features more than 25,000 multiomic datasets.

"For years, BGI has worked with leading companies in the biopharmaceutical space, providing unmatched multiomics analysis services to support precision medicine studies and drug development at different phases," Siqi Liu, cofounder and global head of BGI’s Proteomics Center, said in a statement. "Leveraging deep expertise and 25 years of experience serving the biopharmaceutical and biotechnological industries, I am confident that this strategic partnership will deliver the unique information that customers truly need to make a difference in the fight against cancer."

Financial and other terms of the agreement were not disclosed.